Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
about
A safe lithium mimetic for bipolar disorderImmunotoxicogenomics: gene expression and immunotoxicology in the age of genomicsMicroRNAs in Drug-induced Liver InjuryBioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In VitroChanges in gene expression induced by tienilic Acid and sulfamethoxazole: testing the danger hypothesisCombined computational metabolite prediction and automated structure-based analysis of mass spectrometric data.Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometriesIdiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicitySandwich-cultured hepatocytes: utility for in vitro exploration of hepatobiliary drug disposition and drug-induced hepatotoxicity.Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening.Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity.Irreversible binding of an anticancer compound (BI-94) to plasma proteins.Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications.Computational prediction of human drug metabolism.In vitro screening of drug metabolism during drug development: can we trust the predictions?Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in mice"Omics" Technologies and the Immune System (a) , (b).Deleterious effects of reactive metabolites.Investigative safety science as a competitive advantage for Pharma.Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis.Detecting reactive drug metabolites for reducing the potential for drug toxicity.A high-throughput liquid chromatography/tandem mass spectrometry method for screening glutathione conjugates using exact mass neutral loss acquisition.Development of a screening assay to evaluate the potential of drugs to cause immune-mediated hypersensitivity reactions.Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.Current and Future Challenges for Collaborative Computational Technologies for the Life SciencesThe use of structural alerts to avoid the toxicity of pharmaceuticals
P2860
Q24600175-D2E96A30-D145-4983-8956-E3D1F84F55A9Q24855057-7273809A-7002-48F1-8285-FF67E7D395A3Q26781801-0F9E3E64-BFF8-4294-A829-80108FB1531CQ28552429-EA2B9537-BC4D-4449-A877-C195D61D9FAFQ28578077-CDBC1AF9-7DB4-4A66-94BA-4D0342F07849Q33519657-7983230A-70E7-4697-B34E-08AB731BE023Q33574656-46D4F1DC-4AD7-4466-9EED-2F8003F01854Q34200596-8C83A1B2-83E5-4DFB-857A-3A2C8D606753Q34330504-649A1147-6113-42EA-97F6-F5C7C64789CAQ34663837-40CF0520-8D01-4F9C-9320-199AF2FD2E5AQ35026973-2EAAD180-D97A-4D3E-ACD4-F03C2AE995B4Q36005906-0610345C-76DB-4700-ADC2-46800DF6E465Q36362377-02016690-FDE3-4089-9969-FC8F322AFA65Q36555922-30241ABD-FFFD-4CC6-9322-60EA43507C14Q36572605-636155AA-7F4A-4769-8848-8DF0E865FDE0Q36572626-6376420A-FEDE-41D2-9B42-254EA3FB611BQ37361104-23106F1E-5EFF-485E-B951-A6963FE202E3Q37658722-3DD23C2F-8A48-450A-BE80-A0B34B1A0F0BQ37802740-A1181136-73A7-404E-8AE3-1B840EDED82EQ38024403-E74535DC-7477-48F6-92BE-7E0BC2538CB7Q38271339-99238315-DBE6-4B49-B09C-0DFA2B7FFEABQ38501264-204E8CA9-A5A3-4B34-81D4-EC677F042441Q45268302-3AD323ED-4C80-4100-82C7-99090C1E2FBCQ45789317-4C5BACB9-305A-47D6-AEB3-A5454A82F45DQ54435973-CC3BA832-A62C-4A86-A6D0-942BEA33B681Q56399692-3ACF82AB-ADDC-4BF6-B7A6-085D01FA9F73Q57166595-388D4544-C246-4F9B-8D34-23A754BD35EA
P2860
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
@ast
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
@en
type
label
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
@ast
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
@en
prefLabel
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
@ast
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
@en
P1433
P1476
Screening for the potential of a drug candidate to cause idiosyncratic drug reactions.
@en
P2093
Jack Uetrecht
P304
P356
10.1016/S1359-6446(03)02816-2
P577
2003-09-01T00:00:00Z